Blockchain Registration Transaction Record

VERAXA Biotech Advances FDA-Aligned Methods to Reduce Animal Testing

VERAXA Biotech (NASDAQ: VRXA) updates on FDA-aligned NAMs to cut animal testing in cancer research, advancing BiTAC T cell engagers and antibody-drug conjugates.

This development signals a significant shift in preclinical cancer research, where innovative NAMs can dramatically reduce animal testing while maintaining clinical relevance. By cutting the number of mice needed from over 200 to just 10 in certain studies, VERAXA not only addresses ethical concerns but also potentially speeds up drug development and lowers costs. If widely adopted, such approaches could streamline the path to clinical trials, bringing new cancer therapies to patients faster. Moreover, the validation of VERAXA's BiTAC platform through these methods reinforces the potential of bispecific T cell engagers and antibody-drug conjugates in treating solid tumors, offering hope for more effective and targeted treatments.